Achema middle east

Drug Research

Growing Demand Reshaping The Future of Aseptic Fill Finish

It's important to highlight that aseptic fill finish operations demand skilled personnel, specialized automated equipment, a controlled cleanroom environment, and constant supervision to maintain the sterility and safety of the final pharmaceutical product. Nevertheless, due to the high costs associated...

Biotech Innovations In The Face of Economic Uncertainty

While the pharmaceutical industry has traditionally been seen as recession-proof, with a constant demand for medicines and new treatment options, it currently faces significant challenges. Economic uncertainty is on the rise, increasing the risks associated with early drug discovery,...

Sever Pharma Solutions breaks ground with new high potency drug manufacturing suites

Sever Pharma Solutions, a leading pharmaceutical contract development and manufacturing organization (CDMO), has announced the groundbreaking of its new high potency active pharmaceutical ingredients (HPAPI) manufacturing suites. The company’s investment in these new state-of-the-art manufacturing facilities will allow them...

Bora merges with Sunway Biotech to launch global Nutraceuticals offering

Bora Health, a global design, development and distribution partner of pharmaceuticals and health foods and part of the Bora group, has announced its merged with Sunway Biotech, a leading ingredients manufacturer, and research and development (R&D) organization. Resulting in...

Accelerating Drug Development Through CDMO Partnerships

Based on current market analyses, global pharmaceutical spending is projected to reach approximately $1,742 billion by 2025. Concurrently, spending on COVID-19 vaccines and therapeutics is anticipated to reach around $53 billion worldwide in the same year. Two predominant trends currently...

Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance

Samsung Biologics announced a new agreement with Bristol Myers Squibb for large-scale manufacturing of a Bristol Myers Squibb commercial antibody cancer drug substance. Bristol Myers Squibb and Samsung Biologics have an existing manufacturing agreement for a commercial antibody cancer drug...

As Lonza CEO departs, Catalent scoops up rival CDMO’s bioscience business head to lead biologics

Mere hours after it surfaced that Lonza’s CEO, Pierre-Alain Ruffieux, will step down, the Swiss CDMO has lost another major executive. And this time, the exec is jumping ship to U.S. contract manufacturing rival Catalent. Monday, Catalent named Lonza’s David...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »